Valganciclovir Sup (Valganciclovir Hydrochloride SOLUTION) 50mg/ml X 100ml

Valganciclovir is rapidly converted to ganciclovir after oral absorption. Ganciclovir is then phosphorylated to ganciclovir triphosphate, which competitively inhibits viral DNA polymerase, terminating viral DNA chain elongation and preventing the virus from multiplying.

The dosage of Valganciclovir Sup is determined by a healthcare provider based on the patient's condition, weight, and response to treatment. It is important to follow the prescribed dosage and administration instructions provided by your healthcare professional.

Valganciclovir Sup should be avoided during pregnancy unless directed by a doctor, as it can cause harm to a developing fetus. Breastfeeding individuals should consult a healthcare provider before using this medication to discuss potential risks and benefits.

To order Valganciclovir Sup from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will reply with pricing, availability, shipping, and the import paperwork.

Valganciclovir Sup is specifically designed to treat CMV infections and is often preferred for its convenience as an oral solution. It is converted to ganciclovir in the body, which is effective against CMV. Other antiviral medications may be used for different types of viral infections and may have different mechanisms of action.

Valganciclovir Sup should be stored below 25°C, in the original pack, and protected from moisture. Keep the medication out of reach of children and away from direct sunlight. Follow the storage instructions provided by your healthcare professional to maintain the medication's potency.

Valganciclovir Sup is administered orally as a solution. The medication should be taken as directed by your healthcare provider, typically with a meal to enhance absorption. Follow the prescribed dosage and administration instructions carefully.

The most serious risks associated with Valganciclovir Sup include severe infections like sepsis, blood cell abnormalities such as anemia, neutropenia, and thrombocytopenia, and hypersensitivity reactions. Regular monitoring and blood tests may be required to manage these risks.

Valganciclovir Sup should not be used by individuals who are allergic to valganciclovir or ganciclovir. It should be used with caution in pregnant women, breastfeeding individuals, and those with kidney problems. Always consult a healthcare provider before starting this medication.